Mirati Therapeutics (MRTX) PT Raised to $210 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to Mirati Therapeutics (MRTX) PT Raised to $210 at Piper Sandler
October 28, 2020 5:57 AM EDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00 per share, which consists of 3,960,397 shares to be sold by Mirati and 375,000 shares to be sold by a selling stockholder. The aggregate gross proceeds to Mirati from this offering are expected to be approximately $800.0 million, before... More
October 26, 2020 6:31 AM EDT
Oppenheimer analyst Jay Olson raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $225.00 (from $190.00) while maintaining an Outperform rating.
The analyst commented, "The triple meeting featured MRTX's adagrasib (formerly MRTX849) data in NSCLC and CRC from the KRYSTAL-1 clinical trial. In NSCLC,... More
